Modality
ERT
MOA
TYK2i
Target
B7-H3
Pathway
Complement
ADHD
Development Pipeline
Preclinical
~Jan 2018
→ ~Apr 2019
Phase 1
~Jul 2019
→ ~Oct 2020
Phase 2
~Jan 2021
→ ~Apr 2022
Phase 3
Jul 2022
→ Aug 2028
Phase 3Current
NCT03457764
563 pts·ADHD
2022-07→2028-08·Completed
563 total pts1 indication
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2028-08-152.4y awayPh3 Readout· ADHD
Trial Timeline
Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3
P3
Complet…
Catalysts
Ph3 Readout
2028-08-15 · 2.4y away
ADHD
Completed|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03457764 | Phase 3 | ADHD | Completed | 563 | HAM-D |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Nidasacituzumab | Eli Lilly | Approved | CFTR | |
| LLY-4358 | Eli Lilly | Phase 3 | B7-H3 | |
| Lisonaritide | Eli Lilly | Phase 3 | IL-13 | |
| Ceviglumide | Roche | NDA/BLA | B7-H3 | |
| MRK-2473 | Merck & Co | Phase 1/2 | Nectin-4 | |
| Zorisotorasib | AstraZeneca | Phase 1 | WRN | |
| SNY-9600 | Sanofi | NDA/BLA | B7-H3 | |
| SNY-8628 | Sanofi | NDA/BLA | B7-H3 | |
| SNY-9073 | Sanofi | Phase 2 | B7-H3 | |
| NVO-7840 | Novo Nordisk | Phase 2/3 | B7-H3 |